AFMD | tickerfilter.com

Fundamental analysis

29%

Profitability 25%

Dept financing 15%

Liquidity 71%

Performance 25%

Company vs Stock growth

+ Add row to compare

Performance

5 Days

4.20%

1 Month

-58.67%

3 Months

-62.54%

6 Months

-78.32%

1 Year

177.22%

2 Year

6.90%

Key data

Stock price

$1.30

P/E Ratio

0.00

DAY RANGE

$1.22 - $1.32

EPS

$0.00

52 WEEK RANGE

$0.63 - $8.95

52 WEEK CHANGE

-$73.74

MARKET CAP

64.412 M

YIELD

N/A

SHARES OUTSTANDING

15.227 M

DIVIDEND

N/A

EX-DIVIDEND DATE

N/A

NEXT EARNINGS DATE

N/A

BETA

1.05

PUBLIC FLOAT

AVERAGE 10 VOLUME

$655,355

AVERAGE 30 VOLUME

$552,674

Company detail

CEO: Adolf Hoess
Region: US
Website: affimed.com
Employees: 200
IPO year: -

Issue type: Common Stock
Market: XNAS
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services

Affimed N.V. focuses on discovering and developing cancer immunotherapies. Its lead product candidate is AFM13, which has completed Phase II clinical study for peripheral T-cell lymphoma. The company is also developing AFM24, a tetravalent, bispecific epidermal growth factor receptor, and CD16A-binding innate cell engager, which is in Phase IIa clinical trial for the treatment of advanced cancers.

AFMD - Affimed N.V.